

Amanda Brown

Senior Associate

Philadelphia

Biography

Using her innovative thinking and deep technical knowledge, Amanda Brown (Garger) delivers practical advice to both public and private companies throughout various industries and sectors.

In her practice, Amanda represents a wide range of public and private companies - from clinical-stage life sciences companies to some of the world's largest public companies - and provides trusted advice on matters related to ongoing reporting obligations under U.S. securities laws and regulations, capital market offerings (IPOs, ATMs, RDOs, PIPEs, and convertible notes, among others), corporate governance matters, and more.


Before joining Hogan Lovells, Amanda worked at the Philadelphia headquarters of an international law firm where she advised clients on a range of corporate and securities matters. While in law school, Amanda served as senior staff writer at the *Villanova Law Review*.

Representative experience

A large publicly traded retailer in its ongoing disclosure and reporting obligations.*

A large publicly traded reinsurance company in its ongoing disclosure and reporting obligations and its capital markets transactions.*

A private company in over 10 separate portfolio acquisitions.*



Phone

+1 267 675 4683

Fax

+1 267 675 4601

Email

amanda.brown@hoganlovells.com

Practices

Securities and Public Company Advisory

Corporate Governance and Public Company Representation

Capital Markets

Private Equity

REITs

Mergers and Acquisitions

Industries

Life Sciences and Health Care

Insurance

Real Estate

Consumer

Several clinical and commercial-stage life sciences companies in at-the-market equity offerings led by Jefferies, Cowen & Company, Cantor Fitzgerald, JMP Securities and RBC Capital Markets.

A de-SPAC company in all areas of public company reporting, including on SEC and Nasdaq-related matters.

Enstar Group Limited in two senior notes offerings (each US\$500 million) and two junior subordinated notes offerings (US\$500 million and US\$350 million).

OptiNose in its US\$55 million registered direct offering.

Perspective Therapeutics in its US\$80 million underwritten offering of equity securities.

Perspective Therapeutics in its US\$87.4 million private placement financing.

Perspective Therapeutics on its US\$69 million follow-up public offering of equity securities.

Perspective Therapeutics its series of strategic transactions with Lantheus.

Latest thinking and events

- Press releases
 - Hogan Lovells advises Marinus Pharmaceuticals in sale to Immedica Pharma
- News
 - SEC approves Nasdaq and NYSE revisions to reverse stock split rules: What public companies need to know
- News
 - EDGAR Next Transition Alert: Are you ready for 2025?
- News
 - Publicly Traded Life Sciences Companies and Artificial Intelligence: Disclosing Risk Factors
- Press releases

Areas of focus

- Disclosure and Reporting Obligations
- Stock Exchange Listings and Regulatory Compliance
- Proxy Solicitations, Shareholder Meetings, and Shareholder Proposals
- Raising Equity Capital
- Raising Debt Capital
- Special Committee and Independent Director Representations
- Capital Markets and Tax
- Carve-outs, Spin-offs, and Split-offs
- Compensation Committee
- Initial Public Offerings
- Governance
- Emerging Companies
- Risk Management, Governance, and Compliance
- Section 16 Advice
- Securities and Financial Regulatory Advice

Education and admissions

Education

- J.D., Villanova University School of Law, magna cum laude, Order of the Coif, 2016
 - B.S. Marketing, University of Delaware, 2013
-

- Hogan Lovells advises Perspective Therapeutics in its US\$80 million underwritten offering of equity securities
- Press releases
 - Hogan Lovells represents Optinose in its US\$55 million registered direct offering

Bar admissions and qualifications

Pennsylvania

New Jersey
